Search for Clinical Trial Results
Desmoid Tumor - 26 Studies Found
Status | Study |
Withdrawn |
Study Name: Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors Condition:
Date: 2009-09-15 Interventions: Drug: Hydroxyurea Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients w |
Completed |
Study Name: Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis Condition: Desmoid Tumor Date: 2006-02-06 Interventions: Drug: imatinib mesylate |
Active, not recruiting |
Study Name: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma Condition:
Date: 2009-06-25 Interventions: Drug: Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months |
Recruiting |
Study Name: National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) Condition: Aggressive Fibromatosis Date: 2016-07-15 Interventions:
|
Recruiting |
Study Name: Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets Condition: Desmoid Type-fibromatosis Date: 2015-01-28 Interventions: Drug: Toremifene Patients will receive 60 mg daily and then 180 daily in case of progression |
Recruiting |
Study Name: Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients Condition: Desmoid-type Fibromatosis Date: 2015-01-28 Interventions: Other: Observational approach Patients will be placed under wait and see approach without any specific t |
Active, not recruiting |
Study Name: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Condition: Desmoid-Type Fibromatosis Date: 2014-02-17 Interventions:
|
Recruiting |
Study Name: Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors Condition:
|
Completed |
Study Name: A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome Condition:
Date: 2016-11-02 Interventions: Drug: PF-03084014 Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084 |